Bengaluru, India: April 26, 2016
Biocon Ltd (BSE code: 532523, NSE: BIOCON), Asia's premier biopharmaceuticals company,
announced its Q4 & FY16 results today.
Commenting on the quarterly performance and highlights, Chairperson and Managing Director,
Kiran Mazumdar-Shaw stated:
"Biocon has closed the year with a landmark quarter, crossing a milestone Rs 1,000 Cr
consolidated revenues for the first time. Syngene also closed FY16 on a strong note by crossing
a Rs 1,000 Cr annual revenue mark.
Key developments this quarter were:
1: The Japanese regulatory approval of our Insulin glargine which heralds the entry of our
biosimilars into key regulated markets
2: A Co-development & Commercialization Partnership for Biocon's rh-Insulin for the US
market with Lab Pisa, a leading Mexican Pharma company.
3: An important European approval for Rosuvastatin Calcium Tablets which marks the entry
of our generic formulations foray in developed markets."
"Biocon's gross R&D expenses at Rs 152 crore this quarter were the highest till date reflecting
the advancement of our innovation led drug pipeline comprising novels, biosimilars and
ANDAs. We expect to file a number of regulatory submissions in US and Europe for many of
these programs in FY17," she added.
Highlights of Q4 FY16:
- Biocon recorded Exceptional Income of Rs 268 Cr in Q4, excluding Exceptional Income, Net
Profit for Q4 stood at Rs 105 Cr
- Biocon's Insulin Glargine becomes the first biosimilar from India and 2nd biosimilar glargine to
be approved in Japan.
- Biocon targets the rh-insulin opportunity in the US by collaborating with Lab PiSA, its long
standing partner in Mexico. Pursuant to this, Biocon has recorded an Exceptional Income of Rs
268 Cr on account of the changes in the nature of Biocon's future obligations on the rh-insulin
- EU approval for Biocon's generic Rosuvastatin Calcium tablets will enable the company to take
its first Generic Formulation to the developed markets
- Global Phase III clinical trials for biosimilar Insulin Glargine, Trastuzumab, Pegfilgrastim and
Adalimumab are progressing well towards anticipated filings in FY 17.
- Biocon's quarterly consolidated revenue crosses the Rs 1,000 Cr milestone for the first time in
- Syngene records a strong growth of 32% in Q4FY16 at Rs 316 Cr and crosses the
Rs 1,000 Cr annual revenue milestone in FY16.
- Biocon's gross R&D expenses for the quarter cross Rs 150 Cr indicating the advancement of our
Biosimilars, ANDA and Novel programs.
Key Financials: Q4 & FY16
|In Rs crore, except growth numbers
| Total Sales
| Other Income
| Net Profit
| Gross R&D
| Net Profit
|The figures above are rounded off to the nearest Cr; % based on absolute nos.
*Note: The newly signed co-development agreement for rh-insulin with Lab PiSA changes the nature of Biocon's
future obligations on the rh-insulin program. Hence, the previously deferred amounts of Rs 268 Cr has been
recognized as an exceptional income in the consolidated P& L for Q4 & FY 16.
Restructuring of Legal Entities
Biocon has restructured its legal entities to align with its growth strategies represented by its strategic
business units. We believe this restructuring will enable us to unlock greater value from our business
segments at an opportune time. All our biosimilar assets will now be consolidated under the new legal
entity, Biocon Biologics Limited incorporated in UK as a subsidiary of Biocon Limited, India.
Transition to New India Accounting Standards
From Q1FY17, Biocon will start reporting its financial results based on the new Indian Accounting
Standards, referred to as IND-AS. We do not foresee any significant impact on the earnings from this
Appointment of New Auditors
Biocon's Board of Directors have recommended to shareholders the appointment of BSR & Co LLP as
the new Statutory Auditors of the Company at the upcoming Annual General Meeting on June 30,
Appointment of Mr. M. Damodaran as Independent Director
Biocon has strengthened its Board composition with the induction of Mr. M. Damodaran, a
renowned financial expert and former Chairman SEBI, as an additional Independent Director. He has
served both Central and State Governments in critical positions, besides being on the board of
several leading companies and foreign institutions. After successful stints as Chairman UTI and IDBI
during his career, he has set up Excellence Enablers Private Ltd (EEPL), a Corporate Governance and
Board Advisory consultancy firm. He is also the founder Chairman of IIM, Tiruchirapalli and Chairman
of Glocal Healthcare Systems Pvt Ltd, which provides quality healthcare in rural areas. His presence
will enrich the board and further enhance the quality of governance and compliance at Biocon.
R&D spends crossed Rs 100 Cr in Q4FY16 at the P&L level, an increase of 78% y-o-y, on account of the
clinical advancement of Biosimilars, ANDAs and Novel programs. At a gross level, R&D spends rose
52% to Rs 152 Cr.
Clinical Development of Biosimilars:
The Global Phase III clinical development program for Insulin Glargine has crossed key interim
milestones putting us on track for regulatory filings in US and EU in FY 17. Insulin Aspart & Lispro
collaboration programs are progressing as per plan and are expected to cross critical preclinical
milestones in FY 17.
Monoclonal Antibodies & Proteins
The Global Phase III study for Pegfilgrastim has been completed and it has met the primary endpoint
of demonstrating clinical equivalence with the reference product. The global clinical development of
our other follow-on biologic programs like Bevacizumab, Adalimumab and Trastuzumab is also making good
progress. We are on track for regulatory submissions for some of them in Europe and in the US in
Clinical Development of Novel Programs:
Insulin Tregopil - The Oral Insulin
Biocon is committed to develop Insulin Tregopil for Type I and Type II diabetes patients as a follow up
to the successful outcome of the clinical studies conducted in the US last fiscal. We are in consultation
with our scientific board to design the next clinical study to be initiated in FY17.
Itolizumab - Novel Anti-CD6 MAb
This novel first-in-class anti-CD6 monoclonal antibody is undergoing a bridging Phase I- PK & Safety
study in healthy volunteers in Australia. During the quarter the first sentinel dosing has been
completed. The drug was well tolerated with no adverse effects. The study is expected to enable a global IND filing with a subcutaneous route of administration. Biocon is the first and the only company
globally to clinically validate CD6 as a target for autoimmune diseases.
Biocon in collaboration with Quark Pharma, one of the leaders in small interfering RNA (siRNA)
therapeutics, is developing two siRNA based programs, QPI-1007 and QPI-1024. A pivotal Global Phase
II / III study investigating QPI-1007 in Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)
patients is ongoing.
Novel immune check-point inhibitors have created much excitement in the field of cancer in general
and cancer immunotherapy in particular. Biocon is building an exciting pipeline of fusion MAb
molecules with the concept of preferentially delivering immune modulators to tumor sites thereby,
enhancing efficacy while limiting systemic toxicity. The lead molecule in this program FmAb2 has
achieved preclinical 'proof of concept' and is currently in advanced preclinical development.
During the quarter, Biocon successfully organized an Immuno-Oncology symposium with eminent
scientists in the field such as Prof. Vijay Kuchroo (Harvard), Prof. Gordon Freeman (Harvard) and Prof.
Varsha Gandhi (MD Anderson Cancer Center) as the key speakers.
The overall Sales at Rs 971 Cr registered a growth of 17% in Q4FY16. The Biopharmaceutical segment
delivered sales of Rs 655 Cr, reporting a growth of 11% y-o-y. Within the segment, Biopharma grew
12% delivering Rs 554 Cr, while Branded Formulations reported a growth of 3% with sales at Rs 101
Cr for this quarter.
The Biopharma business reported a growth of 12% fuelled by a strong performance by biosimilars
including insulins and MAbs. Emerging markets contributed significantly this quarter with products
like Trastuzumab and Insulin Glargine being commercialized in additional markets in MENA and South
East Asia. We also partnered for Latin American markets thereby extending our footprint in over 10
The Small Molecules - APIs business continues to report steady sales. We continue to see sustained
margins through a better product mix and are focussed on vertically integrating our API strategy with
our generic formulations business.
An important milestone in this endeavour was our first Generic Formulations approval for
Rosuvastatin Calcium tablets in Europe through the decentralized procedure. This will provide Biocon
access to over 15 European countries with a combined market opportunity of US$ 1.2 billion, starting
Our business rests on a strong foundation and culture of compliance with the highest global quality
Insulins Make Inroads into Japan & USA
During Q4FY16, Biocon received regulatory approvals in Japan, for its world class, ready-to-use,
prefilled, disposable Insulin Glargine pen from the Ministry of Health, Labour and Welfare (MHLW).
The product developed by Biocon is expected to be commercialized in early FY17 by our partner and
aims to capture a significant share of the US$ 144 Mn Japanese Glargine market, which is dominated
by disposable pens and is the second largest market outside of North America & Europe. Biocon's
manufacturing facilities for Insulin Glargine and its state-of-the-art disposable pen assembly facility in
Bangalore were inspected and approved by the Japanese regulatory authorities, prior to granting this
Biocon also entered into a co-development agreement with its long-standing Mexican partner,
Laboratorios PiSA, to target the opportunity for generic recombinant human insulin in the US market.
We see the above developments as significant achievements in our journey of making a global impact
in diabetes management through our affordable biosimilar insulins & analogs. Currently our insulins
are registered in over 65 markets which represent 40% of the global diabetes population.
The Branded Formulations-India business, which underwent product rationalization during the year,
reported sales of Rs 101 Cr in Q4, driven by Metabolics, Onco-therapeutics and Market Access
divisions. Our focus on anchor brands like Insugen®, Basalog®, BIOMAb EGFR®, CANMAb™ and
ALZUMAb™ has enabled them to maintain their positions among the 'Top Three' brands in their
respective segments. The nascent Virology division expanded its product basket with the launch
Daclawin™, an advanced novel therapy for the treatment of chronic Hepatitis-C in India. We have also
increased our prescriber base in order to provide affordable access to patients. Insugen® and Basalog®
command a prescriber base of 26% in the specialty segment, while CANMAb™ is currently the second
preferred brand in its segment with a 20% patient market share. Market Access division continued to
work closely with state and central government institutes to enable affordable access to
biopharmaceuticals for diabetes and cancer, reporting a growth of 33% this quarter.
NeoBiocon in UAE has successfully carved its position at No. 21 amidst the crowded pharma market
dominated by MNCs and local generic companies. For Q4, it reported a strong QoQ growth of 29%,
driven by the branded generics products that cater to the high incidence of lifestyle diseases in the
Research Services - Syngene:
Our Research Services business through Syngene reported a strong revenue growth of 32% to Rs 316
Cr this quarter, driven by a robust performance across three verticals- Discovery Services, Dedicated
Centers and Development & Manufacturing Services. Syngene also crossed a major annual revenue
milestone of Rs 1,000 Cr, with sales of Rs 1,060 Cr in FY16.
Encl: Fact Sheet - Consolidated Income Statement and Balance Sheet (Indian GAAP)
The company will conduct a call at 3.30 PM IST on April 27, 2016 where the senior management will discuss the company’s performance and answer questions from participants. To participate in this conference call, please dial the numbers provided below ten minutes ahead of the scheduled start time. The dial-in number for this call is +91-22-3938 1081/ 6746 5891. Other toll numbers are listed in the conference call invite which is posted on the company website www.biocon.com. The operator will provide instructions on asking questions before the start of the call. A replay of this call will also be available from the conclusion of the call till May 4, 2016 on +91 22 6181 3322/ 3065 2322, Playback ID: 44711. Transcript of the conference call will be uploaded on the company website in due course.
About Biocon Limited
Biocon Limited, publicly listed in 2004, (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013) is India's largest and fully-integrated, innovation-led biopharmaceutical company. As an emerging global biopharmaceutical enterprise serving customers in over 100 countries, it is committed to reduce therapy costs of chronic diseases like autoimmune, diabetes, and cancer. Through innovative products and research services it is enabling access to affordable healthcare for patients, partners and healthcare systems across the globe. It has successfully developed and taken a range of Novel Biologics, Biosimilars, differentiated Small Molecules and affordable Recombinant Human Insulin and Analogs from 'Lab to Market'. Some of its key brands are INSUGEN®(rh-insulin), BASALOG® (Glargine), CANMAb™ (Trastuzumab), BIOMAb-EGFR™ (Nimotuzumab) and ALZUMAb™ (Itolizumab), a ‘first in class’ anti-CD6 monoclonal antibody. It has a rich pipeline of Biosimilars and Novel Biologics at various stages of development including Insulin Tregopil, a high potential oral insulin analog. Visit: www.biocon.com
Q4 FY 16 Financials Fact Sheet: Download
For further information, please contact:
VP & Global Head of Communications
Phone: +91 080 2808 2808
Sr. Manager - Corporate Communications
Phone: +91 080 2808 2808
Head - Investor Relations
Phone: +91 95383 80801
*Mention of "Biosimilar Trastuzumab" refers to Biocon's global programs and has no reference to the Indian sub-continent.
Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking statements. Important factors that could cause actual results to differ materially from our expectations include, amongst others general economic and business conditions in India, our ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currency changes, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global biotechnology and pharmaceuticals industries, increasing competition in and the conditions of the Indian biotechnology and pharmaceuticals industries, changes in political conditions in India and changes in the foreign exchange control regulations in India. Neither our company, our directors, nor any of our affiliates, have any obligation to update or otherwise revise any statements reflecting circumstances arising after this date or to reflect the occurrence of underlying events, even if the underlying assumptions do not come to fruition.